Medical Devices

After a swift restructuring, Modivcare emerges debt-light and privately owned, poised to aggressively invest in technology and transform supportive care.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

A new partnership aims to boost low colorectal cancer screening rates by combining trusted patient education with the promise of simpler blood-based tests.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A new toothbrush using safe microcurrents claims to remove 6x more plaque and cut gum inflammation. Does the science behind this oral care revolution hold up?

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

Establishment Labs has submitted its innovative Motiva implants for FDA approval in reconstruction, promising a new era for post-mastectomy care.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

Diamyd Medical's pivotal Phase 3 trial gets a nine-month acceleration, raising hopes for a new precision therapy that preserves insulin production.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

A new cell-free therapy for the fatal lung disease IPF is heading to clinical trials, thanks to a key manufacturing partnership. Here's what it means.

Swisslog Healthcare appoints Maria Garces from competitor Omnicell as VP, signaling an aggressive push to innovate and dominate the health tech market.

A new class action lawsuit accuses medical device firm Integer Holdings of hiding poor sales while touting growth, leading to a major stock drop.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A landmark executive order reclassifying cannabis is set to unleash a wave of biopharma innovation, validating science-first firms like Avicanna.

A strategic partnership aims to merge respiratory rentals with innovative hygiene products, promising better compliance and comfort for millions of CPAP users.